These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 27572607)

  • 1. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
    Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
    Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
    Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
    J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
    Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
    Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability.
    Raineri A; Fasoli S; Campagnari R; Gotte G; Menegazzi M
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31783660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
    Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
    Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the
    Caporali S; Alvino E; Lacal PM; Ruffini F; Levati L; Bonmassar L; Scoppola A; Marchetti P; Mastroeni S; Antonini Cappellini GC; D'Atri S
    Oncotarget; 2017 Dec; 8(69):113472-113493. PubMed ID: 29371923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
    Lassen A; Atefi M; Robert L; Wong DJ; Cerniglia M; Comin-Anduix B; Ribas A
    Mol Cancer; 2014 Apr; 13():83. PubMed ID: 24735930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
    Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
    Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
    Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M; Ewald F
    Cell Signal; 2015 Nov; 27(11):2191-200. PubMed ID: 26210887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.
    Wang B; Zhang W; Zhang G; Kwong L; Lu H; Tan J; Sadek N; Xiao M; Zhang J; Labrie M; Randell S; Beroard A; Sugarman E; Rebecca VW; Wei Z; Lu Y; Mills GB; Field J; Villanueva J; Xu X; Herlyn M; Guo W
    Oncogene; 2021 Sep; 40(37):5590-5599. PubMed ID: 34304249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
    Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
    Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
    Mohapatra P; Prasad CP; Andersson T
    Mol Oncol; 2019 Feb; 13(2):480-494. PubMed ID: 30582770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
    Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
    Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
    Rittler D; Molnár E; Baranyi M; Garay T; Hegedűs L; Aigner C; Tóvári J; Tímár J; Hegedűs B
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.
    Tian Y; Guo W
    Med Sci Monit; 2020 Apr; 26():e920957. PubMed ID: 32273491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
    Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
    Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.